Latest Hematological malignancy Stories
WHITE PLAINS, N.Y., July 16, 2014 /PRNewswire-USNewswire/ -- James Davis, Ph.D., JD, a consultant in crisis management and the launch of new technologies for biotechnology and other companies,
Failure to get the best treatment and variations in the quality of care are the most likely reasons why survival for blood cancer patients still varies widely between regions within Europe.
- Findings from Phase II clinical study of investigational compound volasertib include response rate and new overall survival data. RIDGEFIELD, Conn., July 8, 2014 /PRNewswire/ --
Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer THOUSAND OAKS, Calif., July 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced
SEATTLE, June 12, 2014 /PRNewswire/ -- CTI BioPharma Corp.
Transparency Market Research added a new report "Global Natural Killer Cell Lymphomas Market: Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store.
- Data include results from two Phase I studies of ABT-199/GDC-0199 in relapsed/refractory chronic lymphocytic leukemia (CLL) and various subtypes of non-Hodgkin's lymphoma (NHL) NORTH
Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology RARITAN, N.J., May 31, 2014 /PRNewswire/
Partnership Set to Raise $250,000 and Provide 12,000+ Hours of Tutoring Services WHITE PLAINS, N.Y., May 29, 2014 /PRNewswire-USNewswire/ -- While extraordinary progress has been made
TG02 also shown to be equally active in CLL cells from patients prior to and following twelve months of ibrutinib therapy. San Diego (PRWEB) May 28, 2014